Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 2Respiratory Aspiration 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × Inhalation × Clear all
NCT06896890 2025-03-26

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Inhatarget Therapeutics

Phase 1/2 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Aspiration

NCT00210080 2015-09-04

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Merck Sharp & Dohme LLC

Phase 3 Completed
700 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡